JP Morgan Chase’s Intersect ENT, Inc XENT Stock Holding History

JP Morgan Chase’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,600	Closed	-$196K	–	6062
2019 Q2	$196K	Sell	8,600 -89,000	-91%	-$2.4M	﹤0.01%	4678
2019 Q1	$3.14M	Buy	+97,600	New	+$3.02M	﹤0.01%	2989
2018 Q3	–	Sell	-32,500	Closed	-$1.22M	–	5908
2018 Q2	$1.22M	Hold	32,500	–	–	﹤0.01%	3709
2018 Q1	$1.28M	Hold	32,500	–	–	﹤0.01%	3540
2017 Q4	$1.05M	Buy	+32,500	New	+$975K	﹤0.01%	3698
2016 Q2	–	Sell	-50,000	Closed	-$950K	–	5051
2016 Q1	$950K	Buy	+50,000	New	+$906K	﹤0.01%	3097

JP Morgan Chase's XENT Position: Q2 2022 in Review

JP Morgan Chase sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 292,931 shares — an estimated $8.2M sold.

JP Morgan Chase first reported a position in XENT in Q3 2014 and held it in 31 quarters. The position peaked at $9.48M in Q3 2021. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

JP Morgan Chase reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
JP Morgan Chase sold 292,931 Intersect ENT, Inc shares in Q2 2022, an estimated $8.2M.
JP Morgan Chase first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 31 quarters.
JP Morgan Chase's Intersect ENT, Inc position peaked at $9.48M in Q3 2021.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.